Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of 1 of the following:

Metastatic or unresectable malignancy for which standard curative or palliative measures do not exist or are no longer effective (phase I) (phase I study closed to accrual as of 8/23/04)
Melanoma (phase I and II)
Measurable disease (phase II)
No history or clinical evidence of CNS disease, including primary brain tumor or brain metastases
Performance status - ECOG 0-1
More than 3 months
WBC at least 3,000/mm^3
Absolute granulocyte count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
No history of bleeding diathesis or coagulopathy
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
AST and ALT no greater than 2.5 times ULN
INR no greater than 1.5
APTT normal
Creatinine no greater than 2.0 times ULN
Creatinine clearance at least 40 mL/min
No proteinuria
Urinary protein less than 500 mg/24 hours
No history of stroke

No uncontrolled hypertension within the past 6 months

Blood pressure less than 150/100 mm Hg on a stable antihypertensive regimen

None of the following within the past 6 months:

Myocardial infarction
Unstable angina
New York Heart Association class II-IV congestive heart failure
Serious cardiac arrhythmia requiring medication
Grade II or greater peripheral vascular disease
Transient ischemic attack
Cerebrovascular accident
Other arterial thromboembolic event
Other clinically significant cardiovascular disease
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier contraception during and for at least 3 months after study participation
No seizures not controlled with standard medical therapy
No prior allergic reactions attributed to Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biological composition to imatinib mesylate
No serious, nonhealing wound, ulcer, or bone fracture
No ongoing or active infection requiring parenteral antibiotics
No significant traumatic injury within the past 28 days
No psychiatric illness or social situation that would preclude study compliance
No other concurrent uncontrolled illness
More than 4 weeks since prior immunotherapy
More than 8 weeks since prior monoclonal antibody therapy
No concurrent prophylactic granulocyte or platelet colony-stimulating factors
More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
No more than 1 prior cytotoxic chemotherapy regimen for advanced disease (phase II)
More than 4 weeks since prior radiotherapy
More than 28 days since prior major surgical procedure or open biopsy
Recovered from prior therapy
No concurrent chronic daily aspirin (greater than 325 mg/day) or nonsteroidal anti-inflammatory drugs known to inhibit platelet function
No recent or concurrent full-dose anticoagulants (except as required to maintain patency of preexisting permanent indwelling IV catheters) or thrombolytic agent
No concurrent grapefruit juice
No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)
No concurrent combination antiretroviral therapy for HIV-positive patients
No other concurrent investigational or commercial agents or therapies directed at the malignancy
No other concurrent investigational agents